FDA assigns Prescription Drug User Fee Act (PDUFA) target date of June 29, 2026Ended 2025 with unaudited cash position of $41 ...
The New Drug Application (NDA) for fostemsavir (ViiV Healthcare), a first-in-class HIV-1 attachment inhibitor for the treatment of HIV-1 infection, has been submitted to the Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results